Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab-Reference-Cited by-同舟云学术

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab

Published:2019-05-14 Issue:5 Volume:14 Page:e0216954
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yamauchi Ichiro^ORCID,Yasoda Akihiro,Matsumoto Shigemi,Sakamori Yuichi,Kim Young Hak,Nomura Motoo,Otsuka Atsushi,Yamasaki Toshinari,Saito Ryoichi,Kitamura Morimasa,Kitawaki Toshio,Hishizawa Masakatsu,Kawaguchi-Sakita Nobuko,Fujii Toshihito,Taura Daisuke,Sone Masakatsu,Inagaki Nobuya

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference20 articles.

1. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies;AK Salama;Ann Oncol,2017

2. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies;DJ Byun;Nat Rev Endocrinol,2017

3. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study;I Yamauchi;Thyroid,2017

4. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab;J de Filette;J Clin Endocrinol Metab,2016

5. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms;DA Delivanis;J Clin Endocrinol Metab,2017

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18F-FDG PET/CT in Renal Cell Carcinoma;Clinical Nuclear Medicine;2024-10

2. Clinical significance of thyroid autoantibodies in differential diagnosis and predicting the course of programmed cell death protein-1 inhibitor-induced thyroid dysfunction;Endocrine Practice;2024-08

3. The nutrition‐related adverse events associated with immune checkpoint inhibitor treatment for patients with non‐small cell lung cancer: A systematic review;Nutrition & Dietetics;2024-05-28

4. Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study;Journal of Endocrinological Investigation;2024-04-29

5. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study;Supportive Care in Cancer;2024-04-10